Can blood plasma from those who have recovered from COVID-19 help those who are currently fighting the virus?
A clinical trial is currently underway in Saskatchewan to see if that’s possible.
The CONCOR-1 clinical trial is examining whether antibodies in human plasma from individuals who have recovered from COVID-19 infection will help treat patients hospitalized with a COVID-19 respiratory illness. It aims to contribute to global efforts to study COVID-19 convalescent plasma as a potential treatment, and is the result of collaboration between the research community and North American blood suppliers Canadian Blood Services, Héma-Québec and New York Blood Center.
“There is currently no proven treatment for COVID-19 infection. Our goal is to understand if the infusion of 500 ml of COVID-19 convalescent plasma will help reduce the severity of illness in adult patients hospitalized with COVID-19 who require oxygen support, but do not yet need a breathing tube,” said Dr. Oksana Prokopchuk-Gauk, Transfusion Medicine Physician for Saskatchewan Health Authority in Saskatoon. Prokopchuk-Gauk is one of two principal investigators in Saskatchewan, alongside Dr. Donna Ledingham in Regina.
Studies of this magnitude are designed, conducted and supported by huge teams of people. The CONCOR-1 Trial team is made up of a multidisciplinary group of experts including physicians, scientists, research coordinators, research assistants, students, biostatisticians, medical laboratory technologists and patient representatives.
Over 50 hospital sites are participating in the CONCOR-1 trial in Canada, with Saskatoon and Regina hospitals open for patient enrolment since the end of July.
“We are relying on our clinical colleagues to contact us if they have patients with COVID-19 under their care who may be interested in hearing more about the CONCOR-1 trial,” noted Prokopchuk-Gauk.
For more information on CONCOR-1,
please visit the website.
Information about convalescent plasma donation can be found on Saskatchewan's
A clinical trial involving blood plasma from convalescent COVID-19 patients is currently underway in Saskatchewan and other parts of North America.